<DOC>
	<DOCNO>NCT00828581</DOCNO>
	<brief_summary>The purpose study evaluate PK property lorcaserin obese overweight elderly subject .</brief_summary>
	<brief_title>Pharmacokinetic Properties Lorcaserin Obese Overweight Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . Males females 2 . Control ( Adult ) group : age 18 65 year ( inclusive ) 3 . Elderly group : age &gt; 65 year ( include subject 1 day beyond 65th birthday ) 4 . Able give sign informed consent 5 . BMI 2745 kg/m2 , inclusive 6 . Eligible male female subject must agree participate conception process ( i.e . active attempt become pregnant impregnate , egg sperm donation , vitro fertilization ) . 6 . Considered stable health opinion Investigator 1 . Prior participation study lorcaserin . 2 . Clinically significant new illness 1 month screen 3 . Not suitable participate study opinion Investigator include exist physical mental condition prevents compliance protocol 4 . History follow cardiovascular condition : Myocardial infarction ( diagnosed cardiac enzyme [ ] and/or diagnostic ECG ) , cerebral vascular accident ( CVA ) , transient ischemic attack ( TIA ) reversible ischemic neurologic deficit ( RIND ) within 6 month screen Cardiac arrhythmia require initiation new medical surgical treatment within 6 month screen ( stable medical therapy &gt; 6 month , pacemaker and/or defibrillator implant &gt; 6 month prior screen acceptable ) Unstable angina History pulmonary artery hypertension 5 . Positive result HIV , hepatitis B hepatitis C screen 6 . Initiation new prescription medication within 1 month prior screen follow exception : 7 . Use SSRIs , SNRIs , medication must meet washout period . 8 . Participated clinical study investigational drug , biologic , device within 1 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>